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Abstract
Background
Chronic kidney disease (CKD) is commonly managed in primary care, but most guidelines
have a secondary care perspective emphasizing the risk of end-stage kidney disease
(ESKD) and need for renal replacement therapy. In this prospective cohort study, we sought
to study in detail the natural history of CKD in primary care to better inform the appropriate
emphasis for future guidance.
Methods and Findings
In this study, 1,741 people with CKD stage 3 were individually recruited from 32 primary
care practices in Derbyshire, United Kingdom. Study visits were undertaken at baseline,
year 1, and year 5. Binomial logistic regression and Cox proportional hazards models were
used to model progression, CKD remission, and all-cause mortality. We used Kidney Dis-
ease: Improving Global Outcomes (KDIGO) criteria to define CKD progression and defined
CKD remission as the absence of diagnostic criteria (estimated glomerular filtration rate
[eGFR] >60 ml/min/1.73 m2 and urine albumin-to-creatinine ratio [uACR] <3 mg/mmol) at
any study visit. Participants were predominantly elderly (mean ± standard deviation (SD)
age 72.9 ± 9.0 y), with relatively mild reduction in GFR (mean ± SD eGFR 53.5 ± 11.8
mL/min/1,73 m2) and a low prevalence of albuminuria (16.9%). After 5 y, 247 participants
(14.2%) had died, most of cardiovascular causes. Only 4 (0.2%) developed ESKD, but 308
(17.7%) evidenced CKD progression by KDIGO criteria. Stable CKD was observed in 593
participants (34.1%), and 336 (19.3%) met the criteria for remission. Remission at baseline
and year 1 was associated with a high likelihood of remission at year 5 (odds ratio [OR] =
23.6, 95% CI 16.5–33.9 relative to participants with no remission at baseline and year 1
study visits). Multivariable analyses confirmed eGFR and albuminuria as key risk factors for
predicting adverse as well as positive outcomes. Limitations of this study include reliance
PLOSMedicine | DOI:10.1371/journal.pmed.1002128 September 20, 2016 1 / 16
a11111
OPEN ACCESS
Citation: Shardlow A, McIntyre NJ, Fluck RJ,
McIntyre CW, Taal MW (2016) Chronic Kidney
Disease in Primary Care: Outcomes after Five Years
in a Prospective Cohort Study. PLoS Med 13(9):
e1002128. doi:10.1371/journal.pmed.1002128
Academic Editor: Giuseppe Remuzzi, Istituto Mario
Negri, ITALY
Received: March 14, 2016
Accepted: August 12, 2016
Published: September 20, 2016
Copyright: © 2016 Shardlow et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: Anonymised data can
be made available to researchers who meet the
conditions of the ethics approval and research
governance policy that applies to this study.
Researchers may apply for data access by contacting
Dr. Teresa Grieve, Research and Development
Manager, Derby Teaching Hospitals NHS Foundation
Trust (teresa.grieve@nhs.net).
Funding: The RRID study is currently funded by a
Research Project Grant (R302/0713) from the Dunhill
Medical Trust (http://www.dunhillmedical.org.uk).
Previous study funding includes a joint British Renal
Society (http://www.britishrenal.org) and Kidney
on GFR estimated using the Modification of Diet in Renal Disease study (MDRD) equation
for recruitment (but not subsequent analysis) and a study population that was predominantly
elderly and white, implying that the results may not be directly applicable to younger popula-
tions of more diverse ethnicity.
Conclusions
Management of CKD in primary care should focus principally on identifying the minority of
people at high risk of adverse outcomes, to allow intervention to slow CKD progression and
reduce cardiovascular events. Efforts should also be made to identify and reassure the
majority who are at low risk of progression to ESKD. Consideration should be given to
adopting an age-calibrated definition of CKD to avoid labelling a large group of people with
age-related decline in GFR and low associated risk as having CKD.
Author Summary
WhyWas This Study Done?
• Chronic kidney disease affects 10%–20% of adults in most countries and is associated
with multiple adverse outcomes, including increased risk of death, progression to end-
stage kidney disease (requiring dialysis or kidney transplantation), and increased risk of
diseases of the heart and arteries.
• The risk of these adverse outcomes varies considerably, and previous studies indicate
that most people with chronic kidney disease are at low risk.
• Many previous studies have been conducted in large teaching hospitals and have under-
standably emphasized the risk of end-stage kidney disease, but the results may not be
applicable to the majority with chronic kidney disease because most have mild disease,
are cared for by family doctors, and are never referred to a kidney specialist.
• We conducted this study to better understand the risks associated with chronic kidney
disease in people cared for by family doctors in order to provide a perspective that is
applicable to the majority of people affected.
What Did the Researchers Do and Find?
• We individually assessed 1,741 people with mild (stage 3) chronic kidney disease at 32
family doctors’ clinics and reassessed them after 1 and 5 y.
• We found that most people (34%) had stable kidney function, only a very small minority
(4 people or 0.2%) developed end-stage kidney disease, and 18% evidenced less severe
progression after 5 y.
• Surprisingly, kidney function improved in some people (19%) to the extent that they no
longer had evidence of chronic kidney disease.
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What Do These Findings Mean?
• Our data emphasize that the management of chronic kidney disease by family doctors
should focus on identifying the minority of people who are at high risk of adverse out-
comes for more intensive treatment and referral to a kidney specialist.
• People at low risk should also be identified so that they can be reassured and spared
unnecessary treatment or referral.
• An internationally agreed definition for “remission” of chronic kidney disease is needed
so that this outcome can be studied in more detail in other populations.
• Our findings may not be directly applicable to populations with younger age or greater
ethnic diversity.
Introduction
In the UK and many other countries, the majority of people with chronic kidney disease
(CKD) are diagnosed and managed in primary care clinics without ever being referred to a
nephrologist. In contrast, most detailed studies investigating the risks associated with CKD
have been led by nephrologists, resulting in a predominantly secondary care perspective. Con-
sequently, guidelines based on these studies tend to emphasize the risk of end-stage kidney dis-
ease (ESKD) and the need for timely referral to facilitate preparation for renal replacement
therapy. Landmark epidemiological studies have highlighted the importance of diagnosing
CKD because the abnormalities that define CKD (reduced glomerular filtration rate [GFR] and
albuminuria) are powerful independent risk factors for multiple adverse outcomes, including
progression of CKD, development of ESKD [1,2], acute kidney injury (AKI) [3], excess cardio-
vascular events (CVEs) [4], and increased mortality [5]. Nevertheless, the prognosis associated
with CKD is extremely heterogeneous, and the risk of adverse outcomes varies widely accord-
ing to the population studied. For example, population-based studies have reported that the
majority of people with CKD are at low risk of developing ESKD [6], whereas studies of people
known to have CKD and managed in secondary care report ESKD as a common outcome
[7,8].
Many previous studies have understandably focused on risks associated with CKD [1–5].
However, it is arguably as important to study positive outcomes such as stable CKD or remis-
sion of CKD so that people at low risk for adverse outcomes can be spared unnecessary inter-
vention and referral to nephrology clinics. Interestingly, there is currently no consensus on
when CKD should be considered no longer present (in remission), and there is therefore a lack
of readily comparable data to indicate how frequently remission occurs or the factors that con-
tribute to it.
The majority of people with CKD in primary care are elderly, and albuminuria is present in
only a minority [9], suggesting that overall this population is at low risk for progression to
ESKD. In this prospective cohort study, we sought to study in detail the natural history of CKD
in primary care to better inform the appropriate emphasis for future guidance on caring for
people with CKD in a primary care setting.
Chronic Kidney Disease in Primary Care
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Methods
Ethics
The Renal Risk in Derby (RRID) study was approved by the Nottingham Research Ethics Com-
mittee 1. All participants provided written, informed consent. The RRID study complies with
the Declaration of Helsinki and the principles of Good Clinical Practice.
Participants
Detailed methods for the RRID study have been published previously [9]. In brief, participants
were individually recruited from 32 primary care clinics in Derbyshire, UK, between 2008 and
2010 and prospectively studied. In total, 8,280 people were invited from registers of people
with CKD stage 3, 1,822 attended baseline visits, and 1,741 were eligible to participate (Fig 1).
Participants were aged>18 y and at least two estimated GFR (eGFR) results (derived from the
Modification of Diet in Renal Disease study [MDRD] equation) of 30–59 ml/min/1.73 m2,
more than 90 d apart, were required to be eligible [10]. People judged to have a life expectancy
of less than 1 y, unable to attend study visits, or with a solid organ transplant were excluded.
Study Visits
Visits were conducted at baseline and repeated at 1 and 5 y. Prior to each visit, participants
completed a background questionnaire covering demographic variables and social, medical,
and medication history. Questionnaires were reviewed at study visits and clarified as required.
Height, weight, and waist and hip circumference were measured. Three blood pressure mea-
surements that differed by<10% were taken using an oscillometric device (UA-767 Plus 30,
A&DMedical) after at least 5 min rest.
Laboratory Methods
Participants were asked to abstain from eating meat for 12 h prior to study visits to avoid con-
founding the serum creatinine assay. Blood and urine samples were analysed in a single clinical
laboratory at the Royal Derby Hospital for standard haematological and biochemical variables.
Creatinine was measured using the Jaffe method, standardized against an isotope dilution mass
spectrometry method. GFR was estimated using the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation in the primary analysis, with an additional sensitivity per-
formed using the MDRD equation. The average urine albumin-to-creatinine ratio (uACR)
from three consecutive early morning specimens was used for analysis.
Thirty-one participants who were unable to attend for year 5 study visits were able to submit
blood and urine samples specifically for the study. For 176 participants, unable to either attend
for a study visit or to submit study samples, we incorporated blood and uACR results taken for
clinical purposes into the dataset. These were selected to be less than 6 mo from the year 5 visit
due date. Samples taken during hospital admissions were not used.
Mortality Data
Date and cause of death as stated on death certificates were obtained from the Office of
National Statistics via the Health and Social Care Information Centre (HSCIC). Independent
of each other and without knowledge of other participant data, three investigators (AS, RJF,
and MWT) assessed the information on death certificates and classified cause of death into
four categories (cardiovascular, malignancy, infection, and other). Differences in classification
were subsequently resolved by discussion.
Chronic Kidney Disease in Primary Care
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Endpoint Definitions
We used Kidney Disease: Improving Global Outcomes (KDIGO) definitions for CKD, CKD
staging, and CKD progression [10]. Progression of CKD was defined as a 25% decline in GFR,
coupled with a worsening of GFR category, or an increase in albuminuria category. Our pre-
specified endpoint from study design (development of ESKD or doubling of serum creatinine)
was not used because of a very small number of events noted during year 5 follow-up. The
Fig 1. Flowchart showing study participant outcomes and follow-up.
doi:10.1371/journal.pmed.1002128.g001
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KDIGO definition was used as an internationally agreed standard of CKD progression that was
observed more frequently in our study population. We defined CKD remission as the presence
of both eGFR>60 ml/min/1.73 m2 and uACR<3 mg/mmol at any study visit in an individual
who had previously met KDIGO diagnostic criteria for CKD.
Statistical Analysis
Analysis was performed using IBM SPSS version 22. Urine ACR was logarithmically trans-
formed prior to multivariable analysis. Outcomes were analysed using binomial logistic regres-
sion models. For analyses of progression and remission, participants with a complete year 5
outcome (eGFR and uACR values or a date of death before the year 5 visit) were included.
Basic models were initially produced including baseline age, eGFR log uACR, and sex. Vari-
ables that were significantly associated with the outcome on univariable analysis were then
added in groups, according to biological and clinical relevance. The final models included all
variables that were significantly associated with the outcome in previous models and gave the
best discrimination. For each model, predicted probabilities were used to draw receiver operat-
ing characteristic (ROC) curves, and area under the ROC curve (AUROC) was used to com-
pare models. Survival analysis was performed using Cox proportional hazards models. All
1,741 participants were included in the survival analysis. Death prior to a year 5 visit was con-
sidered an event. Participants were censored at date of year 5 visit, date of first dialysis, or 5 y
from the time of baseline visit if neither of these events occurred. Three participants underwent
unilateral nephrectomy during the study follow-up period and therefore were excluded from
analysis of CKD progression and remission.
Results
Cohort Description and Outcomes
Description of the cohort at baseline has previously been published [9]. Key baseline variables
are given in Table 1 for the whole cohort and groups according to outcome. Data on renal out-
comes at 5 y were obtained in 1,484 participants (85.2%), and survival data were available in all
participants (from the Office of National Statistics). Two hundred and forty-seven of 1,741
people (14.2%) died prior to their year 5 visit, representing an age-standardised mortality rate
per year of 4.2% in males and 2.2% in females. This compares to a UK age-standardised mortal-
ity rate of 3.9% and 2.9% in males and females, respectively [11]. Four participants (0.2%)
reached ESKD, and 308 (17.7%) evidenced progression of CKD by KDIGO criteria. However,
593 participants (34.1%) had stable CKD, and 336 (19.3%) met our criteria for CKD remission
(Table 1). Year 5 outcomes are reported in Table 2 and summarised in S1 Fig. Outcomes are
further subdivided by baseline CKD category in Table 3 and S2 Fig.
Associations with Progression of CKD
A basic multivariable model that included baseline eGFR, sex, uACR, and age as predictors of
CKD progression was associated with an AUROC of 0.69 (95% CI 0.66–0.74). The addition of
baseline haemoglobin, bicarbonate, diabetes status, and systolic blood pressure (SBP) produced
a model with an AUROC of 0.73 (95% CI 0.69–0.76). In this model, baseline age was not statis-
tically significant. The impact of the change at 1 y in SBP, diastolic blood pressure (DBP), and
eGFR was also assessed. Change in eGFR at year 1 was a significant determinant of CKD pro-
gression, but change in SBP and DBP at 1 y did not enter the model (Table 4). When the
recently validated four-variable Kidney Failure Risk Equation (KFRE) [2,12] was applied to our
study population at baseline, the majority were assessed to be at extremely low risk (median
Chronic Kidney Disease in Primary Care
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5-y probability of ESKD = 0.08%). In the four participants who did progress to ESKD, pre-
dicted 5-y risks at baseline were 54.0%, 33.1%, 14.9%, and 9.0%, respectively.
Associations with All-Cause Mortality
Cause of death was classified as cardiovascular in 94 cases (38.1% of 247 deaths), malignancy
in 63 (25.5%), infection in 50 (20.2%), “other” in 34 (13.8%), and “no data available” in 6
(2.4%). Two people died before year 5 follow-up but after the development of ESKD. Partici-
pants who died tended to be older than other outcome groups and had lower eGFR and higher
uACR on average at baseline (Table 1). Cox proportional hazards models identified age, male
sex, baseline eGFR, log uACR, haemoglobin, albumin, and bicarbonate as independent predic-
tors of death (Table 5). Change in eGFR at year 1 did not enter the model (hazard ratio [HR] =
1.00, p = 0.67).
Table 1. Basic cohort descriptive statistics and breakdown by year 5 outcome.
Variable (n) Total (1,741) Stable CKD
(593)
CKD Remission
(336)
CKD Progression
(308)
Died (247) Lost to Follow-up
(257)
Female Sex (%) 1,052 (60.4) 350 (59.0) 252 (75.0) 160 (51.9) 104 (42.1) 186 (72.4)
Age (years) 72.9 ± 9.0 72.6 ± 8.1 67.1 ± 8.5 73.3 ± 8.7 78.7 ± 6.9 74.9 ± 9.3
eGFR–CKD-EPI (ml/min/1.73 m2) 53.5 ± 11.8 51.6 ± 9.6 64.1 ± 9.0 50.3 ± 11.8 46.3 ± 10.0 55.1 ± 12.0
eGFR–MDRD (ml/min/1.73 m2) 52.5 ± 10.4 50.7 + 8.7 60.9 ± 7.8 49.7 ± 10.9 47.1 ± 95 54.2 ± 10.4
uACR (mg/mmol) 0.3 (0.0–1.5) 0.3 (0.0–1.4) 0.1 (0.0–0.4) 0.9 (0.2–2.1) 1.1 (0.1–3.9) 0.3 (0.0–1.3)
Diabetes (%) 294 (16.9) 93 (15.7) 30 (8.9) 78 (25.3) 57 (23.1) 36 (14.0)
CVD (%) 387 (22.2) 107 (18.0) 49 (14.6) 70 (22.7) 99 (40.1) 62 (24.1)
Current or Previous Smoker (%) 947 (54.4) 307 (51.8) 159(47.3) 173 (56.2) 165(66.8) 143 (55.6)
ACE/ARB use (%) 1,123 (64.5) 374 (63.1) 186 (55.4) 222 (72.1) 173 (70.0) 168 (65.4)
Weight (kg) 78.2 ± 15.5 79.5 ± 14.3 77.6 ± 15.5 79.2 ± 15.8 775 ± 175 75.8 ± 15.6
BMI (kg/m2) 29.0 ± 5.1 29.5 ± 4.9 29.0 ± 5.2 28.9 ± 4.9 28.3 ± 5.4 29.0 ± 5.4
Waist:Hip Ratio 0.91 ± 0.09 0.91 ± 0.08 0.88 ± 0.09 0.92 ± 0.09 0.94 ± 0.09 0.90 ± 0.09
SBP (mmHg) 134.0 ± 18.3 133.7 ± 17.1 130.0 ± 16.8 136.9 ± 17.4 135.7 ± 22.0 134.8 ± 195
DBP (mmHg) 72.8 ± 11.0 73.2 ± 11.0 74.7 ± 10.7 72.2 ± 10.6 70.2 ± 11.6 72.8 ± 11.0
Haemoglobin (g/dl) 13.2 ± 1.4 13.3 ± 1.3 13.6 ± 1.2 12.9 ± 15 12.8 ± 15 13.2 ± 15
Corrected Calcium (mmol/l) 2.38 ± 0.10 2.38 ± 0.10 2.38 ± 0.09 2.37 ± 0.10 2.36 ± 0.10 2.39 ± 0.12
Phosphate (mmol/l) 1.11 ± 0.18 1.10 ± 0.18 1.11 ± 0.18 1.12 ± 0.17 1.11 ± 0.18 1.11 ± 0.18
Albumin (g/l) 40.7 ± 3.2 40.8 ± 2.9 41.4 ± 2.9 40.4 ± 3.6 39.6 ± 35 40.6 ± 3.0
Bicarbonate (mmol/l) 25.5 ± 2.7 25.6 ± 25 26.0 ± 2.5 24.9 ± 2.7 25.4 ± 3.1 255 ± 2.7
Total Cholesterol (mmol/l) 4.8 ± 1.19 4.8 ± 1.2 5.0 ± 1.2 4.7 ± 1.3 4.4 ± 1.1 4.8 ± 1.1
Urate (μmol/l) 384 ± 91 391 ± 89 334 ± 79 402 ± 85 409 ± 100 374 ± 92.8
Change in Given Variables at
Different Time Points
Change in CKD-EPI eGFR at Y1 −0.74 ± 7.8 −0.35 ± 7.4 0.40 ± 8.4 −2.7 ± 7.7 −0.81 ± 8.1 −0.73 ± 7.6
Change in SBP at Y1 (mmHg) −3.2 ± 16.0 −3.4 ± 14.6 −1.8 ± 8.6 −4.1 ± 17.1 −5.0 ± 18.8 −2.1 ± 18.3
Change in DBP at Y1 (mmHg) −2.4 ± 9.3 −2.6 ± 9.1 −1.7 ± 8.6 −2.7 ± 9.3 −2.8 ± 10.0 −2.2 ± 105
Change in uACR at Y1 0.17 (−0.1 to
0.6)
0.15 (−0.1 to
0.4)
0.17 (0.0–0.4) 0.4 (−0.0 to 1.6) 0.3 (−1.1 to
1.3)
0.2 (−0.1 to 0.7)
Change in Weight at Y5 (kg) −1.6 ± 5.9 −1.7 ± 6.2 −1.1 ± 5.4 −1.9 ± 5.9 N/A N/A
Normally distributed variables are presented as mean ± standard deviation (SD). Non-normally distributed variables are presented as median (interquartile
range). Categorical variables are presented as a number (percentage). ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body
mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; N/A, not applicable; SBP, systolic blood pressure; Y1, year 1; Y5, year 5.
doi:10.1371/journal.pmed.1002128.t001
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Associations with CKD Remission
At baseline, participants who evidenced remission at year 5 had a higher mean eGFR and a
lower median uACR, compared to the rest of the study cohort (Table 1). In addition, partici-
pants with remission were younger and evidenced a higher proportion of females (Table 6). A
basic multivariable model, including age, sex, eGFR, and log uACR as independent variables,
was associated with an AUROC of 0.85 (95% CI 0.82–0.87) (Table 6). This was improved to
0.86 (95% CI 0.84–0.88) by addition of the change in eGFR seen at 1 y and baseline haemoglo-
bin. There was no significant difference in weight change between renal outcome groups
(Table 1), nor did weight change enter multivariable models as a predictor of remission.
The number of participants at each time point who demonstrated CKD remission is illus-
trated in Fig 2. Despite meeting KDIGO diagnostic criteria for CKD stage 3 prior to study
entry, 496 participants (28.5%) no longer met the criteria for a diagnosis of CKD at the baseline
study visit. Of this group, 224 (45.2%) remained in remission at year 5. Remission at 5 y was
most likely in the group with remission at both baseline and year 1 (odds ratio relative to those
with no remission at baseline and year 1 = 23.6, 95% CI 16.5–33.9, p< 0.001). Those with
Table 2. Year 5 outcomes and associated independent predictors.
Year 5 Outcome
Stable CKD CKD Remission CKD Progression Died before Year 5
Number of Participants (%) 593 (34.1%) 336 (19.3%) 308 (17.7%) 247 (14.2%)
Independent Predictors Higher eGFR Lower eGFR Lower eGFR
Lower Age Greater Age
Lower uACR Higher uACR Higher uACR
Male Gender Male Gender
Lower Haemoglobin Lower Haemoglobin
Lower Bicarbonate Higher Bicarbonate
Lower Albumin
Previous CVD
Diabetes
Greater Increase in eGFR over 1 y Greater Loss of eGFR over 1 y
doi:10.1371/journal.pmed.1002128.t002
Table 3. Numbers of participants reaching each year 5 outcome by baseline KDIGO CKDGFR and albuminuria category.
CKD Remission Stable CKD
A1 A2 A3 A1 A2 A3
G1/G2 236 (47.5%) 2 (6.3%) 1 (16.7%) G1/G2 102 (20.8%) 14 (43.8%) 3 (50%)
G3a 85 (13.0%) 5 (4.3%) 0 (0%) G3a 268 (40.9) 51 (43.6%) 5 (33.3%)
G3b 6 (2.2%) 1 (1.1%) 0 (0%) G3b 96 (35.3%) 39 (43.8%) 8 (34.8%)
G4 0 (0%) 0 (0%) 0 (0%) G4 4 (21.1%) 4 (28.6%) 0 (0%)
CKD Progression All-Cause Mortality
A1 A2 A3 A1 A2 A3
G1/G2 60 (12.1%) 3 (9.4%) 1 (16.7%) G1/G2 18 (3.6%) 6 (18.8%) 0 (0%)
G3a 114 (17.4%) 25 (21.4%) 2 (13.3%) G3a 88 (13.4%) 23 (19.7%) 4 (26.7%)
G3b 69 (25.7%) 15 (16.9%) 9 (39.1%) G3b 59 (21.7%) 30 (33.7%) 5 (21.7%)
G4 8 (42.1%) 2 (14.3%) 0 (0%) G4 7 (36.8%) 5 (35.7%) 2 (100%)
G1 to G4 refer to KDIGO GFR categories in the classiﬁcation of CKD stage. G190 ml/min/1.73 m2, G2 60–90 ml/min/1.73 m2, G3a 45–60 ml/min/1.73 m2,
G3b 30–45 ml/min/1.73 m2, G4 15–30 ml/min/1.73 m2. A1 to A3 refer to KDIGO albuminuria (uACR) categories in the classiﬁcation of CKD stage. A13 mg/
mmol, A2 3–30 mg/mmol, A3 >30 mg/mmol.
doi:10.1371/journal.pmed.1002128.t003
Chronic Kidney Disease in Primary Care
PLOSMedicine | DOI:10.1371/journal.pmed.1002128 September 20, 2016 8 / 16
remission at baseline only (OR = 5.9, 95%, CI 3.8–9.2, p< 0.001) and year 1 only (OR = 7.1,
95% CI 4.3–11.8, p< 0.001) showed intermediate likelihood of remission at 5 y. The group
with remission at baseline and year 1 also evidenced lower mortality (3.2%) over 5 y compared
with those with remission at baseline only (5.0%) and those with remission at year 1 only
(5.3%). Mortality was significantly lower in all groups demonstrating remission at any time
point compared to the group who met criteria for CKD at both baseline and year 1 (15.7%; log-
rank test p< 0.001).
Sensitivity Analysis
Repeat analyses using the MDRD formula to estimate GFR revealed similar numbers of partici-
pants reaching each outcome. Predictors of different outcomes were similar using MDRD
eGFR to those presented above using CKD-EPI eGFR (S1–S4 Tables).
Discussion
In this population with CKD stage 3 in primary care, the majority of whom did not meet crite-
ria for referral to a nephrologist [13], we observed a very low incidence of ESKD over 5 y
(0.2%), and only a minority evidenced progression of CKD as defined by KDIGO (17.7%). Sim-
ilar to population-based studies, the risk of all-cause (14.2%) and cardiovascular mortality
Table 4. Univariable andmultivariable associations of CKD progression at 5 y.
Variable Univariable Odds Ratio
(95% CI)
Multivariable Odds Ratio (95% CI)
Model 1 (Basic
Model)
Model 2 Model 3 Model 4 Model 5 Model 6 (Best
Model)
eGFR 0.59 (0.51–0.68)* 0.72 (0.62–0.84)* 0.75 (0.64–0.87)* 0.85 (0.71–1.02) 0.74 (0.63–0.86)* 0.82 (0.70–0.97)* 0.71 (0.60–0.85)*
Age 1.41 (1.22–1.62)* 1.25 (1.07–1.45)* 1.25 (1.07–1.45)* 1.22 (1.04–1.44)* 1.12 (0.95–1.32) 1.17 (0.98–1.38) 1.12 (0.94–1.34)
Male Sex 1.70 (1.31–2.21)* 1.24 (0.94–1.64) 1.23 (0.92–1.64) 1.61 (1.15–2.25)* 1.25 (0.94–1.66) 1.50 (1.10–2.03)* 1.48 (1.08–2.02)*
Log uACR 1.76 (1.53–2.04)* 1.59 (1.37–1.85)* 1.56 (1.34–1.81)* 1.59 (1.36–1.86)* 1.56 (1.35–1.82)* 1.53 (1.31–1.79)* 1.50 (1.28–1.75)*
Haemoglobin 0.68 (0.60–0.79)* 0.71 (0.60–0.85)* 0.73 (0.62–0.86)* 0.75 (0.64–0.89)*
Phosphate 1.11 (0.97–1.26) 1.04 (0.89–1.13)
Corrected Calcium 0.78 (0.76–1.00) 0.97 (0.83–0.96)
Bicarbonate 0.71 (0.62–0.82)* 0.83 (0.71–0.96)* 0.83 (0.72–0.96)* 0.83 (0.71–0.96)*
Albumin 0.83 (0.73–0.95)* 0.98 (0.84–1.14)
Total Cholesterol 0.89 (0.78–1.02) 1.10 (0.95–1.27)
Urate (μmol/l) 1.37 (1.20–1.56)* 1.09 (0.92–1.29)
Diabetes 2.22 (1.62–3.06)* 1.71 (1.22–2.40)* 1.53 (1.07–2.19)* 1.52 (1.06–2.20)*
Previous CVD 1.46 (1.06–2.00)* 1.14 (0.82–1.60)
Current or Previous
smoker
1.27 (0.98–1.65) 1.05 (0.79–1.39)
SBP 1.32 (1.15–1.51)* 1.30 (1.09–1.55)* 1.22 (1.02–1.46)* 1.17 (0.98–1.41)
DBP 0.86 (0.76–0.99)* 0.98 (0.68–0.96)* 0.96 (0.80–1.15) 0.97 (0.80–1.16)
BMI 0.92 (0.80–1.05)
Waist:Hip Ratio 1.33 (1.16–1.51)*
Y1 Change eGFR 0.70 (0.61–0.81)* 0.63 (0.54–0.75)*
Y1 Change SBP 0.92 (0.80–1.05)
Y1 Change DBP 0.96 (0.84–1.10)
AUROC (95% CI) 0.69 (0.66–0.73) 0.70 (0.67–0.73) 0.72 (0.69–0.75) 0.70 (0.67–0.73) 0.73 (0.69–0.76) 0.74 (0.71–0.78)
AUROC, area under receiver operator characteristic curve. The eGFR was calculated using the CKD-EPI formula, and all variables were measured at
baseline unless stated. Odds ratios are expressed per 1 SD increase in the independent variable.
* p-value < 0.05
doi:10.1371/journal.pmed.1002128.t004
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(5.4%) greatly exceeded the risk of ESKD [1,14]. Stable CKD (34.1%) was more common than
progression, and a substantial minority evidenced remission of CKD (19.3%).
Our data confirm in a primary care population the previous findings that reduced GFR and
albuminuria are important independent risk factors for adverse outcomes [1–4]. Other risk fac-
tors were similar to those reported in previous studies [15]. In univariable analysis, diabetes
was a significant predictor of CKD progression and mortality. After multivariable adjustment,
diabetes remained an independent predictor only of CKD progression. Nevertheless, as
Table 5. Cox proportional hazardsmodels: Hazard ratios for all-causemortality at 5 y.
Variable Univariable Relative Hazard
(95% CI)
Multivariable Relative Hazard (95% CI)
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6
eGFR 0.50 (0.44–0.57)* 0.69 (0.60–
0.80)*
0.70 (0.60–
0.81)*
0.73 (0.61–
0.87)*
0.71 (0.61–
0.82)*
0.68 (0.57–
0.82)*
0.62 (0.62–
0.84)*
Age 2.47 (2.10–2.89)* 2.01 (1.70–
2.38)*
1.96 (1.66–
2.22)*
1.93 (1.62–
2.30)*
1.99 (1.68–
2.37)*
2.14 (1.76–
2.61)*
1.90 (1.60–
2.25)*
Male Sex 2.20 (1.71–2.84)* 1.62 (1.25–
2.10)*
1.46 (1.12–
1.91)*
1.87 (1.38–
2.54)*
1.67 (1.29–
2.17)*
1.81 (1.34–
2.45)*
1.89 (1.44–
2.49)*
Log uACR 1.57 (1.37–1.81)* 1.30 (1.12–
1.50)*
1.24 (1.07–
1.44)*
1.22 (1.05–
1.41)*
1.31 (1.13–
1.52)*
1.26 (1.07–
1.49)*
1.22 (1.06–
1.41)*
Haemoglobin 0.70 (0.62–0.80)* 0.83 (0.72–
0.97)*
0.84 (0.74–
0.96)*
Phosphate 1.00 (0.88–1.13) 1.00 (0.87–
1.16)
Corrected Calcium 0.86 (0.75–0.98)* 0.97 (0.85–
1.11)
Bicarbonate 0.97 (0.85–1.10) 1.16 (1.02–
1.32)*
1.17 (1.03–
1.32)*
Albumin 0.73 (0.65–0.81)* 0.79 (0.70–
0.91)*
0.82 (0.72–
0.93)*
Total Cholesterol 0.68 (0.59–0.78)* 0.90 (0.77–
1.05)
Urate 1.33 (1.18–1.50)* 1.02 (0.88–
1.17)
Diabetes 1.56 (1.16–2.09)* 1.25 (0.92–
1.68)
1.20 (0.88–
1.63)
Previous CVD 2.62 (2.03–3.38)* 1.84 (1.42–
2.38)*
1.81 (1.39–
2.35)*
Current or Previous
Smoker
1.76 (1.35–2.29)* 1.27 (0.97–
1.68)
SBP 1.10 (0.97–1.25) 0.97 (0.84–
1.12)
DBP 0.76 (0.67–0.86)* 0.90 (0.77–
1.05)
BMI 0.84 (0.74–0.96)*
Waist:Hip Ratio 1.39 (1.23–1.57)*
Y1 Change eGFR 1.00 (0.86–1.16) 0.94 (0.79–
1.11)
Y1 Change SBP 0.89 (0.77–1.04)
Y1 Change DBP 0.96 (0.83–1.12)
The eGFR was calculated using the CKD-EPI equation. All variables were measured at baseline unless stated. Relative hazards are expressed per 1 SD
increase in the independent variable.
* p-value < 0.05
doi:10.1371/journal.pmed.1002128.t005
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diabetes was a predictor of CKD progression, it may have adversely affected survival indirectly
through its effect on GFR. Lower haemoglobin independently predicted both CKD progression
and all-cause mortality [16]. As reported recently by the Chronic Renal Insufficiency Cohort
(CRIC) study investigators, lower serum bicarbonate was associated with CKD progression
[17]. Serum albumin was an independent predictor of mortality, but not CKD progression.
Table 6. Univariable andmultivariable associations of CKD remission at 5 y.
Variable Univariable Odds Ratio
(95% CI)
Multivariable Odds Ratio (95% CI)
Model 1 (Basic
Model)
Model 2 Model 3 Model 4 Model 5 Model 6 (Best
Model)
eGFR 4.92 (3.99–6.06)* 4.07 (3.27–5.07)* 4.01 (3.21–
5.00)*
3.80 (2.99–
4.83)*
4.18 (3.34–
5.24)*
5.25 (4.09–
6.73)*
5.10 (3.97–
6.55)*
Age 0.50 (0.44–0.58)* 0.67 (0.56–0.79)* 0.66 (0.56–
0.79)*
0.70 (0.59–
0.84)*
0.69 (0.57–
0.83)*
0.75 (0.63–
0.90)*
0.76 (0.64–
0.91)*
Female Sex 2.30 (1.74–3.04)* 1.21 (0.87–1.69) 1.22 (0.87–
1.71)
1.44 (0.96–
2.18)
1.16 (0.83–
1.63)
1.16 (0.83–
1.63)
1.34 (0.92–1.94)
Log uACR 0.60 (0.52–0.68)* 0.67 (0.57–0.79)* 0.67 (0.57–
0.79)*
0.68 (0.57–
0.80)*
0.67 (0.57–
0.79)*
0.69 (0.58–
0.81)*
0.69 (0.58–
0.81)*
Haemoglobin 1.33 (1.17–1.53)* 1.22 (1.00–
1.49)*
1.20 (0.99–1.45)
Phosphate 1.01 (0.89–1.15) 1.04 (0.88–
1.23)
Corrected Calcium 1.08 (0.95–1.23) 0.98 (0.83–
1.15)
Bicarbonate 1.32 (1.16–1.51)* 1.17 (0.98–
1.38)
Albumin 1.30 (1.14–1.49)* 1.16 (0.97–
1.38)
Total Cholesterol 1.23 (1.09–1.39)* 0.94 (0.80–
1.11)
Urate 0.52 (0.45–0.61)* 0.96 (0.79–
1.17)
Diabetes 0.42 (0.28–0.63)* 0.79 (0.49–
1.28)
Previous CVD 0.70 (0.50–0.99)* 1.12 (0.73–
1.70)
Current or Previous
smoker
0.79 (0.61–1.01) 0.97 (0.71–
1.32)
SBP 0.74 (0.64–0.85)* 0.87 (0.70–
1.08)
DBP 1.18 (1.04–1.35)* 0.95 (0.78–
1.16)
BMI 0.95 (0.83–1.08)
Waist:Hip Ratio 0.68 (0.60–0.78)*
Y1 Change eGFR 1.22 (1.07–1.38)* 1.71 (1.45–
2.01)*
1.70 (1.44–
2.00)*
Y1 Change SBP 1.13 (0.99–1.30)
Y1 Change DBP 1.11 (0.97–1.26)
AUROC (95% CI) 0.85 (0.82–0.87) 0.85 (0.82–
0.87)
0.85 (0.82–
0.87)
0.85 (0.82–
0.87)
0.86 (0.84–
0.88)
0.86 (0.84–0.88)
The eGFR was calculating using the CKD-EPI equation, and all variables were measured at baseline unless stated. Odds ratios are expressed per 1 SD
increase in the independent variable.
* p-value < 0.05
doi:10.1371/journal.pmed.1002128.t006
Chronic Kidney Disease in Primary Care
PLOSMedicine | DOI:10.1371/journal.pmed.1002128 September 20, 2016 11 / 16
Change in GFR at 1 y was an independent determinant of CKD progression at 5 y. This obser-
vation confirms that annual assessment of GFR is useful for monitoring and as a marker of
prognosis even in people with relatively mild CKD. Overall, the risk of progression to ESKD
was extremely low over 5 y, and less severe CKD progression was observed in only a minority.
The KFRE successfully identified four participants who developed ESKD as moderate or high
risk, but risk prediction tools that predict risk over longer periods or give an estimate of “time
to ESKD”may be more useful in primary care.
Despite globally applied criteria for the diagnosis of CKD, there is no consensus on when
CKD should be considered no longer present (in remission). Therefore, there is a lack of readily
comparable data to indicate how frequently remission occurs or the factors that contribute to
it. Using a definition based on lack of any diagnostic criteria for CKD, we observed remission
in a substantial proportion of people who met the KDIGO criteria for CKD prior to the base-
line study visit. We propose that this observation was in part due to diagnostic considerations.
We recruited participants based on previous routine GFR values estimated using the MDRD
equation. Prior to study visits, participants were asked not to eat meat for 12 h, and for analysis,
the more accurate CKD-EPI formula (published in 2009, after initiation of the study) was used
to estimate GFR. Thus, our data illustrate the importance of applying the most accurate equa-
tion to estimate GFR and avoidance of meat prior to testing (previous studies have reported
that meat ingestion can increase the serum creatinine by as much as 20 μmol/L) [18]. Never-
theless, there were participants who met the diagnostic criteria for CKD at the baseline visit
who evidenced remission at 1 and 5 y (Fig 2). We propose that changes in medication or hydra-
tion status and healing of mild kidney damage may have contributed to this remission. A fur-
ther possibility is that loss of muscle mass with increasing age may result in a decrease in
serum creatinine and a rise in eGFR, but this does not seem to have been a contributory factor
since weight change was not associated with remission in this cohort. Improvement in eGFR
over time has been reported previously in 41% of participants in a large database study (median
7 ml/min/1.73 m2 improvement over 2 y) [19]. This cohort had a similar mean age (76.1 y) to
Fig 2. Flowchart showing numbers of participants demonstrating CKD and CKD remission at each study visit. Arrows indicate numbers of
participants transitioning from one condition to the other.
doi:10.1371/journal.pmed.1002128.g002
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our study, but these participants did not necessarily meet formal definitions for CKD and
included some people with an eGFR>60 ml/min/1.73 m2.
Together, these data make a strong case for an internationally agreed definition of CKD
remission so that it can be studied in other populations. Furthermore, a definition of remission
will allow some patients to be removed from CKD registers, which may have implications for
their health and life insurance. We propose that remission should be defined (in persons previ-
ously diagnosed with CKD) as the absence of diagnostic criteria for CKD that persists for at
least 1 y, since this was associated with a substantially higher likelihood of long-term remission
than a single set of normal values. Remission at any time point was also associated with lower
mortality risk. We have identified lower age, higher eGFR, and lower uACR as predictors of
remission with good discrimination, and these simple variables may therefore be used to iden-
tify patients who should be reassessed for remission or who should perhaps be given a provi-
sional rather than a firm diagnosis of CKD. It remains to be shown, however, whether those
meeting CKD criteria for a short period prior to improvement carry any residual excess risk.
The benign prognosis observed in participants in CKD category G3a A1 raises the question
of whether older people with mildly reduced GFR but no albuminuria should be labelled as
having CKD at all. This is important because our data confirm that G3a A1 represents the larg-
est group of those diagnosed with CKD in primary care (S2 Fig). It has been suggested that an
age-calibrated definition of CKD should be applied to avoid labelling people with age-related
GFR decline and low risk of adverse outcomes as having CKD. Based on an analysis of values
in normal populations across the age spectrum and the risks associated with reduced GFR, it
has been proposed that the GFR threshold for diagnosis of CKD in the absence of albuminuria
in those over 65 y should be lowered from 60 to 45 ml/min/1.73 m2 [20]. Our data support this
recommendation, though it should be noted that progression of CKD over 5 y was observed in
17.4% of those with G3a A1 at baseline, suggesting that monitoring of GFR and uACR in this
group should continue.
Strengths and Limitations
Notable strengths of this study include use of strict KDIGO criteria for diagnosis of CKD stage
3 prior to study entry and detailed clinical characterisation of participants at each study visit.
In this analysis, we have focussed on basic risk factors that would be easily measurable in clini-
cal settings, but the use of novel biomarkers may improve risk prediction in the future.
Our study included predominantly white people, reflecting the demographic composition
of the population of Derbyshire. In addition, the study population was elderly (mean age
72.9 ± 9.0 y), reflecting the higher prevalence of CKD in older people. Although our study pop-
ulation was generally representative of people with CKD cared for in primary care in the UK
[21], the lack of ethnic diversity and relatively high age may limit application of our findings to
populations with different ethnic composition or younger age. Recruitment commenced in
2008, and we therefore used the MDRD equation to diagnose CKD. The MDRD equation is
known to underestimate GFR at higher levels of60 ml/min/1.73 m2 and is less accurate than
the CKD-EPI equation [22]. It is possible, therefore, that some participants were included who
would not have been diagnosed with CKD were the CKD-EPI equation to have been used. Nev-
ertheless, our study reflects a “real-world” situation with some people still having a diagnosis of
CKD based on the MDRD equation. Sensitivity analyses using GFR estimated using the
MDRD equation produced similar results to the primary analysis.
In this analysis, we used KDIGO definitions for CKD progression. The study protocol speci-
fied a definition of ESKD or doubling of serum creatinine as markers of progression, but these
endpoints were met too infrequently to be useful for analysis of our cohort. Nevertheless, we
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believe that analysis using less severe CKD progression as an endpoint remains relevant
because it has been shown that those with greater declines in eGFR are at higher future risk of
ESKD and all-cause mortality [1].
Conclusions
We have observed, in a primary care setting, that the most common outcome associated with
CKD stage 3 over 5 y was stable kidney function. Moreover, a significant minority of people
evidenced CKD remission. Our data therefore suggest that management of CKD in primary
care should focus principally on identifying the minority of people who are at high risk of
adverse outcomes for intervention to slow CKD progression and reduce CVEs. Efforts should
also be made to identify and reassure the majority who are at low risk of progression to ESKD.
Consideration should be given to adopting an age-calibrated definition of CKD to avoid label-
ling a large group of people with age-related decline in GFR and low associated risk as having
CKD. Nevertheless, robust mechanisms should be in place to identify the minority at high risk
for developing ESKD to facilitate timely referral.
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